Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
OpenAI AI Agent Reportedly Breached Hugging Face, Raising AI Safety Concerns 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Intel Stock Slips After Earnings Rally Despite Strong AI-Driven Revenue Growth 
Shein Reports $99 Million Loss Ahead of Hong Kong IPO as U.S. Tariffs Hit Sales 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
When it comes to the red-hot sector of psychedelics, there’s no shortage of companies looking to enter the market. Quantity over quality can be an issue for any new industry, with hundreds of companies scrambling to stake their claim. However, it appears that a leader has emerged in the field. According to a recent survey by StrawPoll, Denver based Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) ranks as the “favourite” publicly traded company in the psychedelic sector.
This comes as no surprise following Mydecine’s recent landmark progress in psychedelic research across the board. This year has been an important one for the company after successfully completing the first legal import of psychedelic mushrooms to Canada. This marks a major first step in the creation of a comprehensive psychedelic supply chain. In addition to Mydecine’s import capabilities, the company has announced an upcoming clinical trial to study the use of psychedelics in the treatment of PTSD. The first-of-its-kind clinical trial is a major step in the company’s goals to revolutionize the treatment of mental health and wellbeing. These trials are global in scope, with research taking place in 7 countries around the world.
Beyond clinical research and design, Mydecine is also innovating in the world of tech, with the creation of a remote mental health service delivery platform called “Mindleap''. It appears the company has effectively diversified and Mydecine’s CEO, Josh Bartch, attributes their recent success to this diverse set of capabilities.
“One thing about Mydecine that’s incredibly unique is that we’re fully vertically integrated, so as it pertains to psychedelic assisted psychotherapy, we really have an A-Z capability.”
Mydecine is quickly becoming the all-in-one brand in the space of psychedelics. With a recent uplisting to the NEO stock exchange, this novel industry leader has significant potential and will be one to watch moving forward.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes.
